+

BR112019005316A2 - anticorpos monoclonais para morte programada 1 (pd-1) - Google Patents

anticorpos monoclonais para morte programada 1 (pd-1)

Info

Publication number
BR112019005316A2
BR112019005316A2 BR112019005316A BR112019005316A BR112019005316A2 BR 112019005316 A2 BR112019005316 A2 BR 112019005316A2 BR 112019005316 A BR112019005316 A BR 112019005316A BR 112019005316 A BR112019005316 A BR 112019005316A BR 112019005316 A2 BR112019005316 A2 BR 112019005316A2
Authority
BR
Brazil
Prior art keywords
antibodies
monoclonal antibodies
relates
programmed death
methods
Prior art date
Application number
BR112019005316A
Other languages
English (en)
Inventor
Yang Baotian
Li Dong
Gololobov Gennady
Xu Jianqing
Li Jing
Zhang Xinhua
Zheng Yong
Tang Zhewei
Wang Zhuozhi
Original Assignee
Cstone Pharmaceutical Suzhou Co Ltd
Cstone Pharmaceuticals
Cstone Pharmaceuticals Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cstone Pharmaceutical Suzhou Co Ltd, Cstone Pharmaceuticals, Cstone Pharmaceuticals Shanghai Co Ltd filed Critical Cstone Pharmaceutical Suzhou Co Ltd
Publication of BR112019005316A2 publication Critical patent/BR112019005316A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

a presente invenção refere-se a anticorpos monoclonais para pd-1, particularmente anticorpos monoclonais humanos para pd-1, que se ligam especificamente a pd-1 com alta afinidade e compreende uma cadeia pesada e uma cadeia leve. a presente invenção se refere ainda a uma sequência de ácido nucleico que codifica os anticorpos da invenção, vetores de clonagem e expressão, células hospedeiras e métodos para expressar ou isolar os anticorpos. imunoconjugados, composições terapêuticas que compreendem os anticorpos da invenção também são fornecidos. a invenção também se refere métodos para tratar vários cânceres com os anticorpos anti-pd-1.
BR112019005316A 2016-09-21 2016-09-21 anticorpos monoclonais para morte programada 1 (pd-1) BR112019005316A2 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2016/099576 WO2018053709A1 (en) 2016-09-21 2016-09-21 The novel monoclonal antibodies to programmed death 1 (pd-1)

Publications (1)

Publication Number Publication Date
BR112019005316A2 true BR112019005316A2 (pt) 2019-09-03

Family

ID=61690082

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019005316A BR112019005316A2 (pt) 2016-09-21 2016-09-21 anticorpos monoclonais para morte programada 1 (pd-1)

Country Status (23)

Country Link
US (3) US11414487B2 (pt)
EP (2) EP3515938B8 (pt)
JP (2) JP7101169B2 (pt)
KR (2) KR102273634B1 (pt)
AU (1) AU2016423559C1 (pt)
BR (1) BR112019005316A2 (pt)
CA (1) CA3037407C (pt)
DK (1) DK3515938T3 (pt)
ES (1) ES3017957T3 (pt)
FI (1) FI3515938T3 (pt)
HR (1) HRP20250400T1 (pt)
HU (1) HUE071253T2 (pt)
IL (1) IL265525A (pt)
LT (1) LT3515938T (pt)
MX (1) MX2019003058A (pt)
PL (1) PL3515938T3 (pt)
PT (1) PT3515938T (pt)
RS (1) RS66679B1 (pt)
RU (1) RU2757316C2 (pt)
SA (1) SA519401370B1 (pt)
SI (1) SI3515938T1 (pt)
SM (1) SMT202500148T1 (pt)
WO (1) WO2018053709A1 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201890468A1 (ru) 2015-08-11 2018-07-31 Уси Байолоджикс (Кайман) Инк. Новые антитела против белка pd-1
HRP20220436T1 (hr) 2015-11-03 2022-05-27 Janssen Biotech, Inc. Protutijela koja se specifično vežu na pd-1 i njihove uporabe
PL3515938T3 (pl) * 2016-09-21 2025-06-09 Cstone Pharmaceuticals Przeciwciała monoklonalne przeciwko programowanej śmierci 1 (pd‑1)
WO2018085358A1 (en) 2016-11-02 2018-05-11 Jounce Therapeutics, Inc. Antibodies to pd-1 and uses thereof
MX2020001328A (es) 2017-08-03 2020-03-20 Amgen Inc Muteinas de interleucina 21 y metodos de tratamiento.
AU2019207895A1 (en) 2018-01-12 2020-06-18 Amgen Inc. Anti-PD-1 antibodies and methods of treatment
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
CA3096460A1 (en) * 2018-04-15 2019-10-24 Immvira Co., Limited Antibodies binding pd-1 and uses thereof
CA3097062A1 (en) * 2018-04-15 2019-10-24 Salubris (Chengdu) Biotech Co., Ltd Antibodies binding pd-1 and uses thereof
CN109160949B (zh) * 2018-07-23 2021-05-14 中国医学科学院血液病医院（血液学研究所） 一种鼠抗人pd-1单克隆抗体及应用
US20220213192A1 (en) * 2019-04-26 2022-07-07 WuXi Biologics Ireland Limited Bispecific antibodies against pd-1 and lag-3
US20220241412A1 (en) 2019-05-24 2022-08-04 Pfizer Inc. Combination therapies using cdk inhibitors
WO2021057836A1 (en) * 2019-09-25 2021-04-01 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
JP2023500385A (ja) * 2019-11-11 2023-01-05 シーストーン・ファーマシューティカルズ・（スージョウ）・カンパニー・リミテッド 医薬組合せ物およびその使用
WO2021110122A1 (zh) * 2019-12-05 2021-06-10 基石药业（苏州）有限公司 Cdk4/6抑制剂的组合疗法
MX2022014974A (es) 2020-05-26 2023-01-11 Boehringer Ingelheim Int Anticuerpos anti-pd-1.
EP4204454A4 (en) * 2020-08-31 2024-07-24 Biosion, Inc. PD-1 BINDING ANTIBODIES AND THEIR USES
WO2022068919A1 (zh) * 2020-09-30 2022-04-07 正大天晴康方(上海)生物医药科技有限公司 结合pd-1抗体的肽及其应用
WO2022118197A1 (en) 2020-12-02 2022-06-09 Pfizer Inc. Time to resolution of axitinib-related adverse events
US20240034796A1 (en) * 2021-02-04 2024-02-01 Genuv Inc. Anti-pd-1 antibody and use thereof
TW202327595A (zh) 2021-10-05 2023-07-16 美商輝瑞大藥廠 用於治療癌症之氮雜內醯胺化合物的組合
WO2023079428A1 (en) 2021-11-03 2023-05-11 Pfizer Inc. Combination therapies using tlr7/8 agonist
CN116036266A (zh) * 2022-12-28 2023-05-02 广州誉衡生物科技有限公司 抗-pd-1抗体及其在制备治疗结肠癌患者的药物中的用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006021955A2 (en) 2004-08-23 2006-03-02 Mor Research Applications Ltd. Use of bat monoclonal antibody for immunotherapy
CA3151350A1 (en) * 2005-05-09 2006-11-16 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
US7662965B2 (en) * 2006-01-26 2010-02-16 Cornerstone Therapeutics, Inc. Anabaseine derivatives, pharmaceutical compositions and method of use thereof
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
WO2013148250A1 (en) * 2012-03-30 2013-10-03 Morphotek, Inc. Tem-1 diagnostic antibodies
JOP20200094A1 (ar) * 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
CN105330740B (zh) 2014-07-30 2018-08-17 珠海市丽珠单抗生物技术有限公司 抗pd-1抗体及其应用
US10822414B2 (en) * 2014-11-11 2020-11-03 Sutro Biopharma, Inc. Anti-PD-1 antibodies, compositions comprising anti-PD-1 antibodies and methods of using anti-PD-1 antibodies
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
EP3253413A2 (en) * 2015-02-06 2017-12-13 Kadmon Corporation, LLC Immunomodulatory agents
EA201890468A1 (ru) * 2015-08-11 2018-07-31 Уси Байолоджикс (Кайман) Инк. Новые антитела против белка pd-1
US11034765B2 (en) 2015-10-02 2021-06-15 Symphogen A/S Anti-PD-1 antibodies and compositions
PL3515938T3 (pl) * 2016-09-21 2025-06-09 Cstone Pharmaceuticals Przeciwciała monoklonalne przeciwko programowanej śmierci 1 (pd‑1)
WO2019062755A1 (en) * 2017-09-29 2019-04-04 Wuxi Biologics (Shanghai) Co., Ltd. BISPECIFIC ANTIBODIES DIRECTED AGAINST EGFR AND PD-1
JP2023500385A (ja) * 2019-11-11 2023-01-05 シーストーン・ファーマシューティカルズ・（スージョウ）・カンパニー・リミテッド 医薬組合せ物およびその使用

Also Published As

Publication number Publication date
SA519401370B1 (ar) 2024-02-27
EP3515938A4 (en) 2020-06-10
HRP20250400T1 (hr) 2025-05-09
US20230014722A1 (en) 2023-01-19
AU2016423559A1 (en) 2019-04-04
JP2019536432A (ja) 2019-12-19
MX2019003058A (es) 2019-11-28
KR102527160B1 (ko) 2023-04-28
AU2016423559B2 (en) 2020-07-30
ES3017957T3 (en) 2025-05-14
FI3515938T3 (fi) 2025-03-27
IL265525A (en) 2019-05-30
RS66679B1 (sr) 2025-05-30
CA3037407A1 (en) 2018-03-29
PT3515938T (pt) 2025-04-10
KR20190072524A (ko) 2019-06-25
EP3515938A1 (en) 2019-07-31
US20240101676A1 (en) 2024-03-28
AU2016423559C1 (en) 2020-11-19
RU2019111277A3 (pt) 2020-10-23
EP4450616A2 (en) 2024-10-23
US20200002420A1 (en) 2020-01-02
RU2757316C2 (ru) 2021-10-13
RU2019111277A (ru) 2020-10-23
EP3515938B8 (en) 2025-04-30
KR102273634B1 (ko) 2021-07-07
SI3515938T1 (sl) 2025-05-30
JP2021120378A (ja) 2021-08-19
US11414487B2 (en) 2022-08-16
WO2018053709A1 (en) 2018-03-29
DK3515938T3 (da) 2025-04-07
KR20210104749A (ko) 2021-08-25
SMT202500148T1 (it) 2025-05-12
EP4450616A3 (en) 2025-01-01
CA3037407C (en) 2022-10-18
LT3515938T (lt) 2025-05-12
HUE071253T2 (hu) 2025-08-28
PL3515938T3 (pl) 2025-06-09
EP3515938B1 (en) 2025-01-08
JP7101169B2 (ja) 2022-07-14

Similar Documents

Publication Publication Date Title
BR112019005316A2 (pt) anticorpos monoclonais para morte programada 1 (pd-1)
ECSP20024555A (es) Anticuerpos especificos para cd47 y pd-l1
MX2023001791A (es) Anticuerpos dirigidos contra receptor de interleucina 36 (il-36r).
BR112019008859A2 (pt) anticorpos direcionados contra a morte programada 1 (pd-1)
ECSP19011185A (es) Proteínas de unión de tipo anticuerpo biespecíficas que se unen específicamente a CD3 y CD123
BR112017014805A2 (pt) anticorpos anti-cd3, anticorpos anti-cd123 e anticorpos biespecíficos que se ligam especificamente a cd3 e/ou cd123
MX2022015901A (es) Proteinas de union biespecificas y usos de las mismas.
BR112018076260A2 (pt) anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina
BR112019008861A2 (pt) anticorpos direcionados contra imunoglobulina de células t e proteína de mucina 3 (tim-3)
BR112017010110A2 (pt) anticorpos contra cd73 e usos do mesmo
BR112018012352A2 (pt) anticorpos anti-lag3 e fragmentos de ligação ao antígeno
BR112017003194B8 (pt) Anticorpo ou fragmento de ligação ao antígeno do mesmo que se liga especificamente a lag3 humano, composição, e, uso do anticorpo ou de um fragmento de ligação ao antígeno do mesmo e da composição
MX383216B (es) Anticuerpos dirigidos contra la inmunoglobulina de células t y la proteína mucina 3 (tim-3).
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
PH12019500571A1 (en) Anti-pd-1 antibodies
BR112016017764A2 (pt) anticorpo antidengue de amplo espectro
BR112013002831A2 (pt) anticorpos direcionados contra a il-17
BR112022003740A2 (pt) Anticorpos anti-cd96 e métodos de uso dos mesmos
EA201691414A1 (ru) Антитела к матриксной металлопротеиназе 9 и способы их применения
BR112022000628A2 (pt) Anticorpos anti-tigit e aplicação dos mesmos
AR109825A1 (es) ANTICUERPOS DE INTERFERÓN b Y USOS DE LOS MISMOS
EA201990927A1 (ru) Антитела против lag-3 и способы их применения
BR112015026823A2 (pt) Polipeptídeo de cadeia pesada de imunoglobulina isolada, polipeptídeo de cadeia leve de imunoglobulina isolada, sequência de ácido nucleico isolada ou purificada, vetor, agente de ligação de proteína de morte-1 programada (pd-1) isolada, célula isolada, composição, e uso do agente de ligação da pd-1 isolada
BR112017001782A2 (pt) fragmentos de anticorpo radiomarcados para uso na prevenção e/ou tratamento de câncer

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载